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PURPOSE. To evaluate the role of nuclear factor–jB (NF-jB) activation in eye drop preservative
toxicity and the effect of topical NF-jB inhibitors on preservative-facilitated allergic
conjunctivitis.
METHODS. Balb/c mice were instilled ovalbumin (OVA) combined with benzalkonium chloride
(BAK) and/or NF-jB inhibitors in both eyes. After immunization, T-cell responses and antigen-
induced ocular inflammation were evaluated. Nuclear factor–jB activation and associated
inflammatory changes also were assessed in murine eyes and in an epithelial cell line after
BAK exposure.
RESULTS. Benzalkonium chloride promoted allergic inflammation and leukocyte infiltration of
the conjunctiva. Topical NF-jB inhibitors blocked the disruptive effect of BAK on conjunctival
immunological tolerance and ameliorated subsequent ocular allergic reactions. In line with
these findings, BAK induced NF-jB activation and the secretion of IL-6 and granulocyte-
monocyte colony-stimulating factor in an epithelial cell line and in the conjunctiva of instilled
mice. In addition, BAK favored major histocompatibility complex (MHC) II expression in
cultured epithelial cells in an NF-jB–dependent fashion after interaction with T cells.
CONCLUSIONS. Benzalkonium chloride triggers conjunctival epithelial NF-jB activation, which
seems to mediate some of its immune side effects, such as proinflammatory cytokine release
and increased MHC II expression. Breakdown of conjunctival tolerance by BAK favors allergic
inflammation, and this effect can be prevented in mice by topical NF-jB inhibitors. These
results suggest a new pharmacological target for preservative toxicity and highlight the
importance of conjunctival tolerance in ocular surface homeostasis.
Keywords: conjunctival tolerance, benzalkonium chloride, allergic conjunctivitis, NF-jB,
conjunctival epithelium, preservative
Local side effects of medical glaucoma treatment represent asignificant challenge in clinical practice because of their
negative impact on patients’ quality of life and compliance.1
Allergic conjunctivitis and dry eye can arise or worsen after
initiating topical treatment with hypotensive eye drops,2–4 and
a significant body of evidence suggests that the microbicidal
agents in glaucoma formulations are responsible for this
phenomenon.1 The most common among the preservatives
approved for human use, benzalkonium chloride (BAK), is
found at concentrations ranging from 0.004% (4 3 103%) to
0.025% (2.53 102%).1 The toxic effects of BAK on the ocular
surface epithelium have been extensively described, encom-
passing apoptosis and/or necrosis induction in vitro5–7 and the
release of proinflammatory cytokines and increased expression
of epithelial activation markers both in vivo and in vitro.8 In
contrast, our understanding of how topical exposure to BAK
facilitates allergic conjunctivitis and dry eye is quite limited,
and there are few reports on the functional impact of the
preservative on ocular surface immunity. We have previously
demonstrated that BAK can profoundly disrupt conjunctival
immunological tolerance to a harmless antigen in mice,9 but the
clinical implications of these findings and the underlying
molecular mechanisms remained unexplored.
The conjunctiva, as we and others have shown,9–11 actively
regulates the immune response when an innocuous antigen
reaches its confines. Under physiological conditions, conjunc-
tival immunological tolerance sets in and requires the migration
of antigen-presenting cells to the draining lymph nodes. The
development of a tolerogenic response involves the expansion
of antigen-specific regulatory T cells12 and prevents unwanted
inflammation on subsequent encounters with the same
antigen.13 This specific function of the conjunctiva has been
proposed as an efficient vaccine delivery route,11 but mucosal
tolerance is not exclusive to the eye. Respiratory immune
tolerance can successfully dampen allergic airway inflammation
and constitutes one of the bases of specific immunotherapy for
asthma.14 Remarkably, and despite extensive research on
bronchial and nasal tolerance, the implications of conjunctival
tolerance (and lack thereof) have not been addressed in the
clinical approach to immune-mediated ocular surface disorders.
In any mucosa, the epithelium plays a key role in the
immune decision-making process by either exerting a tolero-
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genic or an immunogenic conditioning on dendritic cells,15
which in turn drives the expansion of either regulatory or
effector T cells. Activation of the nuclear factor–jB (NF-jB)
pathway in epithelial cells is paramount to this process, and
whereas a low threshold of activity is required for epithelial
homeostasis, chronic engagement of this signaling pathway
leads to T-cell–mediated mucosal inflammation.16,17 On the
other hand, there are numerous examples of how environ-
mental exposure of the skin or mucosal linings to toxic agents
can facilitate an antigen-specific immune response.18–20 Some
of these substances are capable of triggering NF-jB in epithelial
cells and, more importantly, mucosal inhibition of this signaling
pathway can ameliorate disease in animal models.21–23
Based on preliminary findings that suggested a potential
involvement in the immune effects of BAK on cultured
epithelial cells,9 we directly explored the role of the NF-jB
pathway in both BAK toxicity and epithelial–T-cell interaction.
In addition, we hypothesized that exposure to BAK might
facilitate allergic conjunctivitis by the disruptive immune effect
already described.9 To this aim, we designed a murine model of
BAK-facilitated allergic conjunctivitis and evaluated the effect
of topical NF-jB modulation as a therapeutic strategy.
METHODS
Mice
Female Balb/c mice (8–12 weeks old), which were bred and
maintained in our conventional animal facility, were used for
the in vivo experiments. All experiments were approved by the
Institute of Experimental Medicine Animal Ethics Committee
(approval number 20130610) and adhered to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Cell Lines and Cultures
Cell cultures were performed in RPMI 1640 medium supple-
mented with 10% fetal calf serum, 10 mM glutamine, 100 U/mL
penicillin, 100 lg/mL streptomycin, and 5 3 105 M 2-
mercaptoethanol in a humidified incubator with 5% CO2 at
378C. The Pam212 cell line, which was originally derived from
murine epidermal keratinocytes,24 was a kind gift from Adriana
Casas, PhD (Hospital de Cl´ınicas, University of Buenos Aires,
Buenos Aires, Argentina), and was maintained in the same
medium.
Reagents and Antibodies
All reagents were from Sigma-Aldrich (Buenos Aires, Argentina)
unless otherwise specified. Fluorochrome-tagged antibodies
were from BioLegend (San Diego, CA, USA). Grade V
ovalbumin (OVA) was used in all experiments.
Benzalkonium Chloride Treatment of Epithelial
Cells for Supernatant Collection and T-Cell
Cocultures
Confluent Pam212 cells were exposed to fresh medium alone
or with the specified BAK concentration for 15 minutes at
378C, washed twice, and finally cultured in fresh medium
without serum. Nuclear factor–jB inhibitors were added to
some cultures 30 minutes before BAK. After overnight culture,
supernatants were collected and the viability of the remaining
cells was assessed by crystal violet staining. For coculture
experiments, Pam212 cells were grown in 48-well plates and
treated likewise before adding 2 3 105 T cells obtained from
Balb/c mouse lymph nodes. After 4 days of culture, non-
adherent cells were removed by gentle washing and then the
epithelial cells were detached by mild trypsin treatment.
Immunostaining and Flow Cytometry
For surface antigen staining (major histocompatibility complex
II [MHC II], CD40, and CD86), Pam212 cells were washed in
PBS with 0.5% BSA and then incubated with fluorochrome-
conjugated antibodies at previously titrated concentrations for
30 minutes at 48C. For intracellular antigen staining (IjBa),
Pam212 cells were fixed with 4% paraformaldehyde for 30
minutes at room temperature, washed with PBS with 50 mM
glycine, permeabilized, and blocked with 0.1% saponin in PBS
with 5% goat serum for 30 minutes, and then anti-IjBa antibody
(1:100 dilution; Abcam ab32158; Abcam, Cambridge, MA, USA)
was added for another 30 minutes. After thorough washing, the
cells were labeled with DyLight 488 goat anti-rabbit IgG (1:500
dilution; Abcam ab96899) for 30 minutes. For flow cytometry
analysis, cells were thoroughly washed in PBS with 1 mM EDTA
before acquisition on a FACScalibur cytometer (Becton Dick-
inson, Buenos Aires, Argentina). Data were analyzed with
Flowing Software (Perttu Terho, Turku Centre for Biotechnol-
ogy, Turku, Finland; www.flowingsoftware.com). Optimal
compensation and gain settings, as well as viable cell gating,
were determined as previously described.25 Overlayed histo-
gram graphs are plotted in normalized form as percentage of
maximum for each histogram.
Western Blotting
After BAK and/or NF-jB inhibitor treatment, Laemmli buffer
(with 5% 2-mercaptoethanol) was added to Pam212 monolay-
ers, and the resulting extracts were then heated at 958C for 5
minutes and subjected to SDS-PAGE in 10% gel. Proteins were
later transferred from the gel to polyvinylidene difluoride
membranes (Millipore, Billerica, MA, USA) for 2 hours and then
blocked in PBS containing 0.05% Tween 20 and 5% nonfat milk
for 1 hour at room temperature. Membranes were incubated
overnight with anti-IjBa antibody (1:1000 dilution; Abcam
ab32158) and the bound antibodies were visualized with
horseradish peroxidase–conjugated anti-rabbit IgG Abs and the
ECL Western Blotting System (Amersham Biosciences, Amer-
sham, UK). Signal intensity in digital images was quantified
with ImageJ software (http://imagej.nih.gov/ij/; provided in
the public domain by the National Institutes of Health,
Bethesda, MD, USA).
Enzyme-Linked Immunosorbent Assay
Interleukin-6 and granulocyte-macrophage colony-stimulating
factor (GM-CSF) concentrations in culture and explant
supernatants were determined with commercial ELISA kits
according to the manufacturer’s instructions (Peprotech,
Rocky Hill, NJ, USA).
Confocal Microscopy
Pam212 cells grown on coverslips were treated with BAK and/
or NF-jB inhibitors, rinsed with PBS at the specified time
points, fixed for 30 minutes in 4% paraformaldehyde,
permeabilized with ice-cold methanol for 10 minutes, and
washed with 50 mM glycine in PBS. The coverslips were then
incubated with 1 lg/mL polyclonal rabbit anti–NF-jB p65
antibody (sc372; Santa Cruz Biotechnology, Dallas, TX, USA) or
the corresponding isotype control for 2 hours, blocked with
5% goat serum in PBS for 2 hours and then incubated with
DyLight 488 conjugated goat anti-rabbit IgG (1:100 dilution) for
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2 hours. Coverslips were finally mounted with 1 lg/mL
propidium iodide using antifade medium. Images were
acquired with a FluoView FV1000 confocal microscope
(Olympus, Tokyo, Japan) equipped with a Plapon 360/1.42
objective and analyzed with Olympus FV10-ASW software.
Conjunctival Instillation of BAK, OVA, and NF-jB
Inhibitors and Parenteral Immunization
Phosphate-buffered saline, 102% BAK, 20 lg OVA (2 mg/mL),
0.1 mM pyrrolidine dithiocarbamate (PDTC), and 0.5 mM
sulfasalazine (SSZ) or different combinations of these com-
pounds in PBS were instilled daily in a volume of 5 lL to the
conjunctiva of both eyes for 5 days. On day 7, mice were
injected subcutaneously in the flank with 0.1 mL of 1:1
complete Freund’ s adjuvant (CFA) emulsion in PBS containing
100 lg OVA.
Conjunctival Explants
Mice were instilled PBS or BAK alone or combined with 0.1
mM PDTC and 0.5 mM SSZ in both eyes once daily for 3 days
before euthanasia. The tarsal conjunctivas were excised under
aseptic conditions with the aid of a dissection microscope, as
described elsewhere.9 The conjunctival explants from each
animal (approximately 30 mg tissue) were pooled, washed
three times with PBS, and then cultured in 1 mL medium
without serum. Supernatants were collected after 24 hours for
further analysis.
Myeloperoxidase Colorimetric Quantification
Assay
Conjunctival explants from each mouse were rendered into a
suspension with a tissue homogenizer in 0.3 mL PBS and then
0.5% Triton X-100 was added. Suspensions were then
centrifuged at 2000g for 5 minutes and the supernatants
collected for enzymatic assay. In brief, 50 lL 1-Step Ultra TMB-
ELISA Substrate Solution (Thermo Scientific, Waltham, MA,
USA) was added to 50 lL of each sample in duplicate in
microtiter plates and incubated at room temperature for 15
minutes, after which the reaction was stopped by adding 50 lL
1 N sulfuric acid. Absorbance was measured at 450 nm with
the reference filter set at 570 nm.
Measurement of Delayed-Type Hypersensitivity
Responses
Mice were immunized after conjunctival instillation as de-
scribed above. A group of untreated mice served as a negative
control. On day 15, OVA (100 lg in PBS) and PBS alone were
injected in a volume of 50 lL into the right and left foot pads,
respectively. Antigen-induced swelling was measured 48 hours
later as the mean difference in thickness between the right and
left foot pads of each mouse.
T-Cell Proliferation Assays
Single-cell suspensions were obtained by mechanical dissoci-
ation of spleens and sieving through wire mesh. For antigen
proliferation assays, 2 3 105 cells were cultured for 3 days in
96-well plates containing 100 lg/mL OVA, and 1 lCi per well
of [3H]-thymidine was added for the final 18 hours. Thymidine
incorporation was measured by liquid scintillation counting
and the results of triplicate cultures are expressed as the mean
stimulation index 6 SEM, calculated as the ratio of counts per
minute in antigen-containing cultures to the counts in control
cultures.
Ocular Antigenic Challenge and Assessment of
Allergic Response
Groups of three mice were treated as detailed in the figure
legends and 2 weeks after parenteral immunization, they were
challenged with 5 lL of 250 mg/mL OVA in each eye. Twenty-
four hours later, each eye was photographed before euthanasia.
Clinical inflammation was graded by a masked observer
according to a previously validated scale26 that considers lid
edema, chemosis, conjunctival redness, and tearing and
discharge. The eye globes with the attached lids were excised
and immediately fixed in 10% buffered neutral formalin.
Histopathological Study
Formalin-fixed eye specimens were embedded in paraffin,
serially cut into vertical 5-lm-thick sections, and stained with
hematoxylin and eosin. Six to eight sections from each sample
were examined for evaluating the conjunctival tissue and
inflammatory cells.
Immunohistochemistry
Immunohistochemical detection of NF-jB p65 was performed
on formalin-fixed, paraffin-embedded sections using the ABC
technique. Briefly, after endogenous peroxidase activity was
inhibited by 3% H2O2 and microwave antigen retrieval was
performed, sections were blocked with 2% normal goat serum,
then incubated overnight with polyclonal rabbit anti-NF-jB
p65 antibody (sc372, dilution 1:100; Santa Cruz Biotechnolo-
gy), rinsed three times with PBS, incubated with a biotin-
conjugated secondary antibody (1:200 in PBS, 3% normal goat
serum; Vector Laboratories, Burlingame, CA, USA) for 30
minutes at room temperature, rinsed three times with PBS and
finally incubated with ABC peroxidase (horseradish peroxi-
dase) complex (Vector Laboratories) for 30 minutes at room
temperature. The reaction was developed with 3,30-diamino-
benzidine (3 lg/mL in PBS with 0.5% H2O2) and controlled
under the microscope. Specimens were lightly counterstained
with hematoxylin before mounting. Primary antibody was
omitted in the negative control.
Statistical Analysis
Student’s t-test and ANOVA with Dunnett’s post hoc test were
used to compare means of two and three or more samples,
respectively. Significance was set at P < 0.05 (two-tailed tests)
and calculations were performed using GraphPad Prism 5
software (GraphPad Software, La Jolla, CA, USA).
RESULTS
Benzalkonium Chloride Induces NF-jB Pathway
Activation in Cultured Epithelial Cells
As the epithelial NF-jB pathway plays a key role in
determining the immune outcome in other mucosal sites,
we reasoned that it could be involved in the disruptive effect
of BAK on conjunctival tolerance that we had previously
reported.9 Therefore, we directly assessed by different
approaches the activation status of the NF-jB pathway in
epithelial cells on BAK treatment. As primary murine
conjunctival epithelial cells could not be obtained in sufficient
number by standard culture techniques,27 we used the
Pam212 epithelial cell line, which we had previously used
for exploring the immune effects of BAK.9 To model the
instillation of a BAK-containing eye drop onto the ocular
surface, we exposed Pam212 monolayers for 15 minutes (the
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accepted tear film clearance time28,29) to a BAK concentration
curve starting at 102% (0.01%, the most frequently used
concentration in medical formulations), and extending up to
1000-fold dilution (105%). We have previously shown that
104% and 103% BAK treatment for 15 minutes does not affect
Pam212 cell viability on overnight culture, whereas compara-
ble exposure to 102% BAK readily induces cell death.9 First
we quantified the expression of the IjBa protein, an inhibitory
cytoplasmic protein that binds the NF-jB complex and
prevents its translocation to the nucleus. Benzalkonium
chloride decreased IjBa protein levels in epithelial cells, as
did lipopolysaccharide (LPS), a well-characterized activator of
the NF-jB pathway (Fig. 1A). These results, obtained by FACS,
were confirmed by Western blot under the same conditions
(Fig. 1B). We also determined by immunofluorescence
microscopy the actual intracellular location of the NF-jB
transcriptional complex in Pam212 cells. Strict cytoplasmic
localization of the NF-jB p65 subunit was detected in resting
cells, whereas significant translocation to the nucleus was
observed 1 h after BAK treatment (Fig. 1C). Altogether these
results show that a brief exposure to BAK is sufficient to
trigger the NF-jB pathway in cultured epithelial cells.
FIGURE 1. Benzalkonium chloride triggers NF-jB activation in epithelial cells. (A) Confluent Pam212 monolayers were exposed for 15 minutes to
different BAK concentrations. Then cells were trypsinized, fixed, and permeabilized and the intracellular expression of IkBa protein was analyzed by
FACS. Representative histograms are shown: isotype control (gray histogram), basal expression (filled histogram), and after exposure to BAK
(black histogram). Bar graph (n ¼ 3) of IjBa expression relative to unstimulated cells under different BAK concentrations and 1 lg/mL LPS
stimulation. Asterisk indicates a statistically significant difference with unstimulated cells (ANOVA with Dunnett’s post hoc test). (B) Pam212 cells
were treated as described in (A) and then whole cell extracts were prepared to evaluate IjBa levels by Western blot. Shown are representative
immunoblots of three independent experiments (left) and the relative IjBa expression after BAK treatment (right). Asterisk indicates a statistically
significant difference with unstimulated cells (ANOVA with Dunnett’s post hoc test). (C) Pam121 cells were exposed for 15 minutes to 103% BAK,
washed twice, and cultured for an additional hour before fixation and NF-jB p65 staining. Representative micrographs (n¼ 3) show NF-jB p65 in
green and cell nuclei in red (propidium iodide staining).
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Benzalkonium Chloride–Exposed Epithelial Cells
Release Proinflammatory Cytokines and Express
MHC II in an NF-jB–dependent Fashion
To assess whether NF-jB activation has functional immune
consequences in epithelial cells, we collected culture super-
natants of Pam212 cell monolayers that were briefly exposed
to BAK. Two well-characterized NF-jB activation inhibitors,
SSZ and PDTC, were added to some cultures before BAK
treatment. The SSZ inhibits IjB kinase by competing for the
adenosine triphosphate binding site,30 whereas PDTC acts
downstream in the NF-jB activation cascade by blocking the
ubiquitylation of IjB protein.31 Thus, both inhibitors act
independently and prevent the degradation of IjB, which in
turn inhibits the nuclear translocation of NF-jB dimers. On
BAK exposure, we found that Pam212 cells released increased
levels of IL-6 and GM-CSF, two cytokines whose transcription is
enhanced by NF-jB, and more importantly, that this release
could be reversed by pretreating the cells with either PDTC or
SSZ (Fig. 2A). To evaluate additional functional effects of BAK
on epithelial cells, we focused on MHC II expression, a widely
accepted marker of epithelial activation that is associated with
ocular surface damage in glaucoma patients.32 We assessed by
FACS the levels of MHC II and CD40 and CD86 costimulatory
molecules in Pam212 cells, but could not detect the expression
of any of them under basal conditions or after BAK treatment.
As MHC II expression in epithelial cells is dependent on
interferon c stimulation,33,34 we reasoned that this in vitro
setup lacked the T cells usually found in the conjunctiva as a
potential source for this cytokine. Therefore, we added
syngeneic T cells to the epithelial cell cultures and found a
significant increase in the MHC IIþ epithelial cell fraction after
4 days of coculture (Fig. 2B). Major histocompatibility complex
II expression was further enhanced in a dose-dependent
fashion when the epithelial cells were previously exposed to
BAK, and remarkably, the increase was completely inhibited by
pretreating the epithelial cells with either PDTC or SSZ. By
contrast, coculture with T cells induced neither CD40 nor
CD86 expression in epithelial cells (data not shown).
Altogether, these results show that BAK-induced NF-jB
activation in Pam212 cells is sufficient to increase proinflam-
matory cytokine secretion, such as IL-6 and GM-CSF, and
indirectly augments MHC II expression by affecting their
interaction with T cells.
FIGURE 2. Benzalkonium chloride induces IL-6 and GM-CSF release and favors MHC II expression by epithelial cells. Pam212 cells were exposed to
different BAK concentrations for 15 minutes, thoroughly washed, and cultured further. For some experiments, NF-jB inhibitors (inh) were added to
the cultures 30 minutes before BAK treatment. Either 10 lM PDTC (P) or 0.5 mM sulfasalazine (S) at were used. (A) Bar graph (n¼ 4) of IL-6 and
GM-CSF concentrations in 18- h supernatants as assayed by ELISA. Asterisk indicates a statistically significant difference compared with control
cultures, according to ANOVA with Dunnett’s post hoc test. (B) Major histocompatibility complex II expression in Pam212 cells after 96 hours of
culture with and without T cells. (Left) Representative experiment with isotype control (light gray histogram), untreated epithelial cells alone
(filled histogram), untreated epithelial cells with T cells (black histogram), and BAK-treated epithelial cells with T cells (dashed histogram).
(Right) Bar graph (n¼ 6) of pooled data. Asterisk indicates a statistically significant difference compared with control Pam212–T-cell cocultures,
according to ANOVA with Dunnett’s post hoc test.
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Benzalkonium Chloride Induces Conjunctival
Epithelial NF-jB Activation and Proinflammatory
Effects In Vivo
To validate our in vitro findings, we explored ocular surface
changes in mice exposed daily to 102% BAK in both eyes. We
assayed NF-jB activation in the conjunctival epithelium by
immunohistochemistry after 3 days of treatment (Fig. 3A),
observing increased expression of NF-jB p65, and more
importantly, nuclear p65 localization throughout the epithelial
layer in BAK-treated but not in control mice. These changes
were abrogated by adding 0.1 mM PDTC (Fig. 3A) or 0.5 mM
FIGURE 3. Benzalkonium chloride induces NF-jB activation in the conjunctival epithelium in vivo and proinflammatory changes. Groups of three
mice were instilled daily for 3 days with saline or 102% BAK combined or not with NF-jB inhibitors (inh): 0.1 mM PDTC (P) or 0.5 mM sulfasalazine
(S), and then the eyes were surgically excised for analysis. (A) Representative immunohistochemical images of conjunctival tissue with NF-jB p65-
specific staining. Increased epithelial p65 expression is evident only in BAK-treated eyes, with nuclear staining in the superficial epithelial cells (red
arrows) (IHC DAB staining, 3200). (B) Bar graph (n ¼ 3) of IL-6 concentration in 18-hour culture supernatants from ocular explants. Asterisk
indicates a statistically significant difference compared with saline-treated mice, according to ANOVA with Dunnett’s post hoc test. (C) Bar graph (n
¼ 3) of peroxidase enzymatic activity in whole-eyelid homogenates. Asterisk indicates a statistically significant difference compared with saline-
treated mice, according to ANOVA with Dunnett’s post hoc test.
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SSZ (data not shown) to the BAK formulation. We also detected
increased production of IL-6 (Fig. 3B), but not of GM-CSF (data
not shown), in ocular explants of mice that were topically
treated with 102% BAK. Again, this effect was completely
inhibited by concomitant administration of either of the two
NF-jB inhibitors. As BAK favored conjunctival neutrophil
infiltration in other models,35 we quantified the number of
conjunctival inflammatory cells in whole eyelid homogenates
by a peroxidase enzymatic assay (Fig. 3C). We detected a
significant increase in peroxidase levels in BAK-treated mice
that was blocked by simultaneous delivery of NF-jB inhibitors.
Altogether these results show that ocular exposure to BAK
triggers epithelial NF-jB activation and other inflammatory
changes in mice.
Topical NF-jB Inhibitors Restore Conjunctival
Tolerance in a Murine Model of BAK Toxicity
We have previously shown that BAK skews the ocular surface
milieu in such a way that mice fail to develop mucosal
tolerance to a harmless antigen (OVA) that is topically given at
the same time. Instead, the mice develop a Th2-like proin-
flammatory response.9 To assess if topical NF-jB inhibitors
could affect the conjunctival immune outcome, we instilled
preparations containing OVA, 102% BAK, and inhibitors in
different combinations once daily for 5 days and then evaluated
the systemic immune response, as represented in Figure 4A.
On subsequent challenge (Fig. 4B), we detected reduced
antigen-specific cellular responses in OVA-treated but not in
BAKþOVA-treated mice, confirming the disruptive effect of the
preservative on conjunctival tolerance. When either PDTC or
SSZ were included in the antigen preparations, conjunctival
tolerance was not affected. However, the addition of these
inhibitors to the BAKþOVA preparations reversed the systemic
effect induced by BAK. We also obtained comparable results in
vivo by evaluating the delayed-type hypersensitivity response
to OVA (Fig. 4C). Our findings show that topical NF-jB
inhibitors can restore conjunctival tolerance in BAK-treated
mice.
Exposure to BAK Facilitates a Conjunctival Allergic
Response in a NF-jB–Dependent Fashion
To investigate the potential clinical implications of breakdown
of conjunctival tolerance to harmless antigens, we evaluated
the magnitude of ocular allergic responses in a widely accepted
murine model that involves active immunization. As depicted
in Figure 5A, mice were instilled OVA with and without BAK
and/or NF-jB inhibitors daily for 5 days to induce a
conjunctival T-cell response,9 and then they were immunized
with the same antigen in adjuvant to elicit an effector T-cell
response. Two weeks later, the pathogenic potential of the
effector T-cell response was assayed by topical challenge of
both eyes with OVA. Tolerized (OVA-treated) mice developed
less conjunctival inflammation than their nontolerized (un-
treated) and BAK-exposed cage mates (Figs. 5B, 5C), highlight-
ing the protective role of this mucosal function. Addition of an
NF-jB inhibitor to the conditioning phase resulted in reduced
allergic responses in both OVA and BAKþOVA mice. These
results indicate that conjunctival tolerance is capable of
protecting from subsequent antigen challenge, and that topical
NF-jB inhibitors favor its development even under BAK
exposure. Histopathological analysis of enucleated eye samples
was consistent with the clinical assessment of allergic changes
(Fig. 6). Congestive vessels, edema, and inflammatory cells
(predominantly eosinophils) were observed in the lamina
propria mucosae of the palpebral and bulbar conjunctiva of
immunized-only and OVA- and BAKþOVA-instilled mice. Com-
pared with OVA-instilled mice, eosinophil infiltration was
slightly more abundant in the conjunctiva of BAKþOVA-instilled
mice but it was similar in OVAþPDTC- and OVAþSSZ-instilled
mice. Interestingly, samples from mice receiving
BAKþOVAþPDTC or BAKþOVAþSSZ showed fewer, if any,
eosinophils. Altogether these results suggest that conjunctival
tolerance can protect from an allergic reaction and that topical
NF-jB inhibitors favor tolerance even under BAK exposure.
DISCUSSION
Immune tolerance has become a powerful ally in the
management of asthma13 and chronic inflammatory bowel
disease,36 but its role in ophthalmological practice has not yet
been addressed. In this work we show that immune tolerance
is involved in ocular surface homeostasis and that its disruption
could explain the exacerbation of ocular allergy that frequently
affects patients treated with BAK-containing eye drops. In
addition, we demonstrate that in vitro exposure of epithelial
cells to this preservative leads to proinflammatory changes that
resemble those already described in patients, and more
importantly, that these changes can be reverted by well-
characterized NF-jB inhibitors. From these results, we suggest
FIGURE 4. Topical NF-jB inhibitors prevent conjunctival tolerance
disruption by BAK. (A) In vivo model of conjunctival tolerance under
BAK exposure. Groups of three mice were instilled in both eyes daily
for 5 days with 2 mg/mL OVA with and without 102% BAK in different
combinations with NF-jB inhibitors (inh): 0.1 mM PDTC (P) or 0.5 mM
sulfasalazine (S). On day 7, mice were subcutaneously immunized
(imm) with OVA in CFA, and 2 weeks later, the T-cell response was
assayed. (B) Bar graph (n ¼ 6) of OVA-specific proliferation in
splenocyte cultures as assayed by [3H]-thymidine incorporation.
Proliferation is expressed as stimulation index (counts per minute in
the presence of antigen/counts per minute without antigen) of each
treatment group relative to untreated immunized mice. Asterisk
indicates a statistically significant difference compared with saline-
treated mice, according to ANOVA with Dunnett’s post hoc test. (C)
Bar graph (n ¼ 3) of OVA-induced delayed hypersensitivity response,
expressed as the difference in swelling between the OVA-injected and
the saline-injected footpad of each mice. Asterisk indicates a
statistically significant difference compared with untreated, unimmu-
nized mice according to ANOVA with Dunnett’s post hoc test.
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that modulation of this pathway could have a role in the
management of ocular surface disease.
Benzalkonium chloride exerts deleterious effects on con-
junctival epithelial cells, in part by producing reactive oxygen
species and inducing apoptosis.6 Here we demonstrate that
BAK also triggers NF-jB activation in epithelial cells in vitro,
even at concentrations 100- and 1000-fold lower than those
used in glaucoma formulations (Fig. 1). At such reduced levels
of BAK, we observed little impact on cell viability after 15
minutes of exposure. Nevertheless, we still detected functional
consequences of NF-jB activation, such as increased produc-
tion of IL-6 and GM-CSF by epithelial cells (Fig. 2A).
Pretreatment with NF-jB inhibitors completely prevented this
effect, and validating these in vitro findings, we observed the
same pattern in IL-6 production by ex vivo ocular surface
explants (Fig. 2B). Our results are in line with previous reports
on BAK32 and other related preservatives37 and probably
reflect a common epithelial response to injury that involves
NF-jB activation. A similar effect has been described for
cigarette smoke, another inducer of oxidative stress, on
primary cultures of bronchial epithelial cells and immortalized
cell lines.38
In addition to increased IL-6 levels in tear samples,
expression of MHC II in conjunctival epithelial cells constitutes
another marker of ocular surface inflammation in patients
treated with BAK-containing eye drops.32 In our in vitro
system, BAK alone did not induce expression of this
inflammatory marker, a finding consistent with the already
described dependence of epithelial cells on exogenous
interferon c for MHC II expression.33,34 As T lymphocytes
and NK cells are the major producers of interferon c, we added
T cells to the cultures to model the conjunctival lymphoid
population. Under these conditions, we observed that expo-
sure to BAK increased epithelial MHC II expression, in
agreement with the clinical reports. Moreover, prior NF-jB
inhibition completely abolished this effect, suggesting that
activation of this signaling pathway in epithelial cells somehow
conditions neighboring T cells to favor interferon c produc-
tion. It remains to be established whether augmented MHC II
expression in conjunctival epithelial cells represents simply a
bystander effect of increased T-cell activation or if it plays any
role in potentiating ocular surface inflammation. A consider-
able limitation of in vitro systems involving epithelial cell
monolayers to mimic mucosal linings is that these cells
FIGURE 5. Topical NF-jB inhibitors protect from BAK-facilitated allergic conjunctivitis. (A) In vivo model of allergic conjunctivitis after BAK
exposure. Groups of three mice were instilled in both eyes daily for 5 days with 2 mg/mL OVA with and without 102% BAK in different
combinations with NF-jB inhibitors (inh): 0.1 mM PDTC (P) or 0.5 mM sulfasalazine (S). On day 7, mice were subcutaneously immunized (imm)
with OVA in CFA, and 2 weeks later, both eyes were challenged with OVA alone. Clinical assessment was performed 24 hours later. (B) Clinical score
of ocular inflammation as detailed in the Methods section. Shown are mean 6 SD of 3 animals/group. Asterisk indicates a statistically significant
difference compared with OVA-challenged immunized mice, according to ANOVA with Dunnett’s post hoc test. (C) Representative photographs
from one experiment showing the effect of PDTC and sulfasalazine (SSZ) instillation in OVA- and BAKþOVA-treated mice.
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FIGURE 6. Topical NF-jB inhibitors protect from BAK-facilitated allergic conjunctivitis. Histopathological analysis of eyes obtained by enucleation
48 hours after antigen challenge, as described in Figure 5. Representative micrographs from conjunctival sections from one experiment (n¼ 3) are
shown. Infiltrating eosinophils are marked by a blue asterisk . Note the absence/paucity of eosinophils in BAKþOVAþPDTC and BAKþOVAþSSZ mice
(hematoxylin-eosin staining,3400).
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produce high levels of TGF-b on contact with T cells, which in
turns leads to late inhibition of T-cell activation.39–42 In any
case, our results suggest that the increased MHC II expression
observed in treated glaucoma patients could be the end result
of BAK promoting epithelial–T-cell interaction and not a direct
effect of BAK on the ocular surface epithelium.
We have previously reported that topical BAK prevents the
induction of conjunctival tolerance in mice,9 and in this work
we show that concomitant administration of NF-jB inhibitors
abolishes the proinflammatory effect of the preservative.
Remarkably, both inhibitors when instilled alone had no effect
on tolerance induction (Fig. 4), which involves the generation
of antigen-specific regulatory T cells.9 The NF-jB pathway
contributes to epithelial homeostasis,16 and its complete
inhibition in epithelial cells results in severe mucosal and/or
skin inflammation in genetically modified mice.43,44 In line
with these reports, we observed reduced epithelial cell
viability in vitro after exposure to BAK in the presence of
NF-jB inhibitors.9 On the other hand, excessive NF-jB
activation in epithelial cells promotes mucosal inflammation,
and there are numerous reports of disease improvement by
local administration of NF-jB inhibitors in murine models.21,22
Pharmacological inhibition does not differentiate whether the
effect is limited to either the epithelial lining or mucosal
immune cells or if it encompasses both cell populations. More
importantly, it does not imply complete epithelial inhibition of
the NF-jB pathway, which seems to be proinflammatory by
itself.43,44 In agreement with this hypothesis, we did not
observe inflammatory changes in the conjunctiva of mice
treated with NF-jB inhibitors alone.
Until recently, conjunctival tolerance had not been consid-
ered in the pathophysiology of ocular surface inflammation.
Stern et al.45 proposed that dry eye could be conceived as a
mucosal autoimmune disease in which breakdown of immu-
nological tolerance leads to ocular surface inflammation. To
the best of our knowledge, there are no reports on the possible
role of conjunctival tolerance in immune exacerbations of
ocular surface disease that frequently affect medically treated
glaucoma patients.2–4 In this work, we show that prior ocular
exposure to an antigen markedly hampers allergic conjuncti-
vitis in systemically immunized mice. It is noteworthy that
ocular challenge was performed with an antigen dose 125-fold
higher than that used for tolerization, highlighting the
powerful protection afforded by conjunctival tolerance.
Conversely, exposure to BAK abrogated this beneficial effect,
suggesting a possible mechanism by which local allergic
reaction might be facilitated in patients. Finally, topical NF-jB
inhibitors did not affect conjunctival tolerance, but were able
to prevent its breakdown by BAK in our model. Altogether,
these results suggest that mucosal tolerance plays a key role in
ocular surface immune homeostasis, and that NF-jB modula-
tion could be a pharmacological target to reduce BAK adverse
effects while at the same time maintaining its microbicidal
effect and pharmacokinetic advantages.
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